Fatty acid interactions with genetic polymorphisms for cardiovascular disease

Caren E. Smith and José M. Ordovás
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA

Abstract

Purpose of review—The number of studies investigating interactions between genes and nutrients for cardiovascular disease continues to grow, and holds tremendous potential for reducing disease risk at the level of the individual genotype. However, understanding the limitations and challenges of interaction studies, whether of observational or interventional design, is essential for critical evaluation of these studies.

Recent findings—Nutrient-gene interactions for cardiovascular disease both parallel and extend nutrition studies, encompassing both traditional and novel cardiovascular risk factors. Fatty acid quality, lipid metabolism, inflammation, post-prandial metabolism, fatty liver and macronutrient-gene interactions for obesity and metabolic syndrome represent a subset of the major areas of recent focus. With few exceptions, however, reports of gene-nutrient interactions are limited to a single population.

Summary—Gene-nutrient research will continue to expand as genome wide association studies uncover new sources of genetic variability associated with cardiovascular risk. However, in addition to investigation of newly discovered variants, continuing efforts must focus on the confirmation of previously reported genetic associations and interactions in additional populations.

Keywords
nutrient-gene interactions; cardiovascular disease; fatty acids

Introduction

Analyses of the role of gene-nutrient interactions in the risk of cardiovascular disease (CVD) address the fundamental question of inter-individual variation in the response to diet, and lay the groundwork for construction of a genetically-based framework for tailoring diets to minimize disease risk. The predominant analysis approach relies on candidate gene association and interaction studies, in which genes are selected based on known functions of the proteins they encode, and evaluated for their associations with outcomes in populations. In the case of interaction studies, modulation of a genetic association by nutrients (usually intake, but also biomarkers reflecting intakes and metabolism), energy intake or a
phenotype, such as obesity, are evaluated for specific outcomes. Phenotypic outcomes are usually intermediate risk factors (eg, lipids, glucose and insulin, anthropometrics) rather than vascular end-points (eg, myocardial infarction, atherosclerotic lesion), and the following review is organized by outcome. Regardless of the specific outcome, however, individual genetic effect sizes tend to be small, and obtaining adequate sample size to capture relatively small effects is a frequent challenge. False positive results are another potential pitfall associated with multiple testing of metabolic outcomes or variants. In response to these challenges, replication of gene-nutrient interactions in independent populations has become critical but is still relatively rare. While collaborative data sharing arrangements have provided greater opportunity for replications, heterogeneity introduced by genetic and cultural factors in populations of differing ethnicities further complicates analyses, as many of the included studies illustrate.

Myocardial Infarction/Atherosclerosis

Investigation of gene-nutrient interactions for endpoints such as myocardial infarction (MI) or atherosclerosis is less common due to the complexity of the outcome, but these outcomes have been examined in a few recent studies (1,2••,3). Pro-inflammatory leukotrienes, which are derived from arachidonic acid (AA) in the 5-LO (lipoxygenase) pathway, appear to play a proatherogenic role in people. A 5-LO promoter polymorphism was shown to be associated with carotid atherosclerotic lesions, and to interact with dietary fatty acids in a US population (n=470) which included non-Hispanic whites, Hispanics, Asian or Pacific Islanders, Blacks, and others. In this cohort, AA and linoleic acid were associated with increased atherosclerosis (intima-media thickness) in carriers of the variant allele, and omega-3 fatty acids were protective in carriers (3). More recently, the same group demonstrated a similar interaction in a Costa Rican population (n=3770) for the related outcome of MI (2••). Replication of interactions between 5-LO genotype and fatty acids in two independent populations of different ethnicities supports the plausibility of a biological relationship between fatty acids and 5-LO genotype. While a previous study had failed to reproduce the association for the outcome of MI in a smaller (n=688) Spanish population, this study did not evaluate the role of dietary factors, which differ considerably among US, Costa Rican and Spanish populations. (4).

Lipids

Genetic associations (5) and fatty acid-gene interactions continue to be widely explored for lipid outcomes (6,7). A growing body of studies focus on peroxisome proliferator-activated receptor (PPAR) variants, a series of nuclear receptors which are activated by long chain fatty acids. PPARα regulates genes involved in glucose and lipid metabolism as well as atherosclerotic lesion formation, and responds to triglyceride (TG)-lowering medications, such as fibrates, as well as long chain polyunsaturated fatty acids. One widely studied single nucleotide polymorphism (SNP), PPARA L162V, was shown in earlier studies to be associated with lipids and CVD risk, and recently reported to interact with PUFA in a US White population for plasma TG concentrations (8). Evaluation of fatty acids interaction for this SNP and 8 others was performed in two US populations comprising the ARIC study (n=10,134 Whites and n=3480 Blacks) (9). In spite of the large samples in the current study, particularly for Whites, the previously reported L162V interaction with PUFA was not reproduced. Of 8 other SNPs tested, two showed interaction with PUFA, one (3’UTR G→A) interacted with omega-6 PUFA to modulate total cholesterol and low density lipoprotein cholesterol (LDL-C) only in Whites and another (3’UTR C→T) interacted with omega-3 PUFA to modulate the same lipids only in Blacks. Detection of interactions for two different SNPs and two types of PUFA in the two populations is not unexpected, given large differences in minor allele frequencies (MAF) for the SNPs in the two groups, combined
with significant differences in omega-3 and omega-6 intakes in the Blacks and Whites studied. Interaction $P$ values were nominal (0.02–0.03) in the context of large samples used to evaluate a large number of outcomes and SNPs, suggesting that additional studies in ethnically appropriate populations would be useful.

Although the previous study reported omega-3 fatty acid modulation of cholesterol, omega-3 fatty acids have been most widely investigated for their modulation of TG. Omega-3 fatty acids lower TG, and intra-individual variability in this response may be related to genetic variability. CD36 encodes a class B scavenger receptor which interacts with a wide variety of ligands including long chain fatty acids and oxidized LDL-C, and which has been implicated in atherosclerosis and insulin resistance. Evaluation of potential relationships between four CD36 SNPs, omega-3 fatty acids and lipids was performed in a UK population of healthy, middle-aged White men ($n$=111) (10). CD36 genotype modulated fish oil–associated changes in TG such that for three of the four SNPs, TG was significantly lower only in homozygous carriers of the G allele, which was minor in three SNPs and major in the other. This study did not replicate associations for non-esterified fatty acids (NEFA) demonstrated in the larger study from which the SNPs were selected (11). Additional studies with larger populations would be useful in confirming the novel interactions reported here.

The preceding interactions focused on fasting lipids, but recognition of the critical impact of postprandial lipemia on CVD risk has led to a large number of association and interaction studies designed to assess the impact of genotype on the response to oral fat loads (12). Hepatic lipase (LIPC) plays a key role in the lipid metabolism, especially for high density lipoprotein cholesterol (HDL-C). While the LIPC -514 C/T variant has been widely studied, several other promoter variants including LIPC -250G/A are in linkage disequilibrium with this SNP in Whites. In a small group of healthy male Spanish students (GG genotype $n$=30 and A carrier genotype $n$=21), the presence of the A allele for the -250 G/A SNP was associated with a greater postprandial response, which was most pronounced for small TG-rich lipoproteins (13). The same group previously demonstrated a lower postprandial response for carriers of the variant allele for LIPC -514 (14), which raises questions about the functional nature of each SNP and potential interaction among LIPC SNPs.

Extending the preceding studies are those investigating the effects of background dietary intakes of fatty acids on genetically based differences in the postprandial response. Variants of the transcription-factor 7-like 2 (TCF7L2) gene have been associated with impaired insulin secretion, metabolic syndrome traits, and altered postprandial lipoprotein response, although results have not been consistent (15,16) and nutrient interactions for postprandial lipid metabolism are unexplored for this gene. Warodomwichit et. al. hypothesized that differences in diet among populations might influence baseline metabolic associations for TCF7L2, as well as postprandial responses (17). In a study of 1083 US Whites, they showed that the TCF7L2 variant rs12255372 interacted with dietary PUFA for fasting very low density lipoproteins (VLDL), and the postprandial response (TG, chylomicrons, VLDL and large VLDL). For each lipid outcome, a more atherogenic profile was associated with the variant allele (T) only in the context of high PUFA intake. While these data provide a plausible explanation for inconsistent results from previous association studies, the authors note that a large number of tests were performed in a single population, and recommend confirmation in additional populations.

While the preceding studies have evaluated fatty acid interactions using dietary intakes, concentrations of specific plasma fatty acids which may interact with genes are determined both by both intake and metabolism (18–23). Specifically, the activity of key enzymes (eg, desaturases) encoded by genes in the FADS cluster contribute to PUFA concentrations. A
recent genome-wide association study using the Italian InCHIANTI population (n=1075) (24••) which evaluated signals associated with plasma PUFA reported strong associations for the \textit{FADS1}, \textit{FADS2}, and \textit{FASD3} clusters as well as for the \textit{ELOVL2} gene which encodes enzymes involved in the elongation of PUFA. Five SNPs were chosen for replication in the US GOLDN population (n=1076 Whites). Of the five SNPs, one \textit{FADS1} SNP (rs174537) showed patterns similar to those in InCHIANTI for linoleic acid, AA, alpha linolenic acid (ALA), eicosapentanoic acid (EPA) as well as total cholesterol and LDL-C. A second \textit{ELOVL2} SNP (rs953413) was also strongly associated with docosapentanoic acid (DPA) in the GOLDN population and DHA in both populations. Although not an interaction study, this confirmation study by Tanaka et al. identifies sites at which genetic variability in enzymes metabolizing essential fatty acids interacts with diet to alter specific plasma fatty acid concentrations, potentially modulating genetic risks in subsequent metabolic pathways.

**Obesity**

Lipids represent one of the earliest CVD risk factors to be investigated genetically, but recognition of genetic susceptibility to obesity and its contribution to CVD risk via lipid and glucose metabolic dysregulation is growing (25–29). Obesity is highly heritable, but may be modifiable through dietary composition as well as energy intake. Two recent studies have reported interactions between genetic variants and monounsaturated fatty acids (MUFA) for obesity-related outcomes (30•,31•). Variants of the adipocyte-derived protein adiponectin have been previously linked to obesity and insulin resistance, but association studies among different ethnic groups have not been consistent. In a population of 1083 US Whites, the –A allele of the adiponectin 11391 G>A variant was protective against obesity independently of dietary intake and also under conditions of high MUFA intake, but this relationship was reversed (eg, the A variant was associated with increased obesity risk and BMI) in subjects consuming low intakes of MUFA (30•). Additional interactions for PUFA intake were observed for the same SNP, but did not achieve significance after correction for multiple testing, suggesting that a larger sample might yield additional interactions.

MUFA intake also interacted significantly with variants of \textit{WDTC1}, the human ortholog of the \textit{Adipose} gene, which was shown to be associated with obesity in \textit{Drosophila sp.} (31•). Although \textit{WDTC1} was associated with obesity in two populations, US Whites (n=1115) and Caribbean Hispanic Americans (n=935), the patterns were slightly different and reached significance only in women in the Whites. Further, MUFA was protective for AA subjects for the i22835A>G variant and associated with increased BMI for GA and GG subjects only in the Caribbean Hispanics. The partial replication demonstrated for obesity in the two populations likely reflects not only genetic heterogeneity, but also the wide phenotypic and dietary variability documented in these two groups.

**Metabolic Syndrome and Diabetes**

As obesity prevalence has increased globally, rising rates of related conditions such as metabolic syndrome and diabetes have stimulated exploration of associated genetic risks (32,33). Two recent studies have reported interactions between fatty acid intake and genetic variants for regulators of lipid metabolism, the PDZ-Interacting domain of the Scavenger Receptor Class B Type I and δ6-desaturase (encoded by \textit{FADS2}) (34,35). In a study of 1000 US Whites, the T allele of the PDZK1_i33968C>T variant was associated with metabolic syndrome, but the relationship was differentially modified by intake of PUFA and carbohydrate, depending on obesity status (34). Replication of the complex relationships between gene, diet and obesity observed in this overweight population with metabolic syndrome prevalence of 30% is desirable.
In a second study performed in a Costa Rican population (n=1815) with metabolic syndrome prevalence of 36%, the prevalence ratio of metabolic syndrome decreased in subjects with increasing quintiles of adipose tissue ALA (35). This effect trended towards interaction (P=0.08) with the FADS2 rs3834458 genotype. Mechanistically, the reported interaction is plausible although novel, since δ6-desaturase mediates the conversion of ALA and linoleic acid to longer chain PUFA, and the same group previously demonstrated lower long-chain PUFA in Costa Rican carriers of the variant FADS2 allele (36). Exploring the role of fatty acids which compete with ALA for δ6-desaturase, such as linoleic acid, and metabolic syndrome in other populations may yield additional relevant data, since the study authors note that Costa Rican intake of linoleic acid is low compared to other groups.

In addition to metabolic syndrome, investigators have examined gene-nutrient interactions for the components of the syndrome including impaired glucose metabolism. Dietary fat quality may alter glucose metabolism such that saturated fat is associated with increased insulin resistance while unsaturated fats are associated with improved insulin sensitivity. Plasma adiponectin concentration is also positively associated with insulin sensitivity, but whether adiponectin and diet interact to modify glucose metabolism is unexplored (37). In a cross-over intervention examining three test diets in healthy Spanish students (n=59 men and women), dietary fat interacted with adiponectin genotype. In men only, homozygotes for the C allele of the -11377 C>G variant demonstrated less insulin resistance following a carbohydrate-rich or MUFA-rich diet compared to the saturated fat-rich diet. (38•). Results from previous studies evaluating the -11377 C>G variant and insulin sensitivity have been mixed, and results from the current study suggest that dietary factors may be one source of variability. However, the small sample size and the limitation of the observed relationship to men in the dietary trial warrant additional investigation in larger groups.

Gender-specific interactions were also reported for omega-3 fatty acids and glucose and fatty acid metabolism outcomes, according to genotype of the PPARγ variant Pro12Ala. (39). PPARγ modulates lipid metabolism and adipocyte differentiation through control of gene expression. Omega-3 fatty acids and PPARγ each appear to play roles in glucose metabolism, and the current study explored potential interactions in 571 Finns. In women, fish and omega-3 intake interacted with PPARγ for postprandial 2-hour glucose whereas in men plasma DHA interacted with PPARγ for serum free fatty acid concentration. In both instances interaction P values were nominal in the context of a large number of tests, and the metabolic outcomes were observed for different genotypes in men and women (eg, male Pro homozygotes benefited from high DHA but in women high fish intake was beneficial for Ala carriers). Gender differences for both PPARγ associations and long-chain omega-3 fatty acid metabolism have been previously reported (40,41) but additional studies would help to confirm the reported interactions.

**Nonalcoholic Fatty Liver Disease**

While the outcomes discussed above contribute to CVD risk, nonalcoholic steatohepatitis (NASH) has been shown to predict risk independently of other factors (42). Mechanisms for this relationship are not well understood, but plasma adiponectin appears to plays a major role in postprandial lipemia, NASH and CVD risk (43). In the current study, Musso et.al. examined adiponectin variants 45TG and 276GT for their relationship to NASH and postprandial lipemia following oral fat load in 70 NASH cases and 70 matched controls (44). Genotypes 45TT and 276GT/TT were more common in patients with disease, associated with greater disease severity, with lower adiponectin in controls, with higher postprandial response and with lower postprandial adiponectin compared to other genotypes. While the study did not evaluate nutrient gene interactions, and may have lacked statistical power to do so, subjects with NASH showed higher intake of saturated fat and lower intake...
of PUFA than controls. A third study by the same group identified a relationship between PUFA and saturated fatty acid ratio, TCF7L2 genotype and the postprandial glucose-dependent insulinotropic peptide response in NASH (45). In light of these observations and those reported for fatty acids and adiponectin variants for obesity and insulin sensitivity (6,30•), investigation of modulation of adiponectin-related genetic risk by diet may suggest ways to ameliorate disease severity in people with NASH.

Conclusions

Gene-nutrient interaction studies have the potential to reduce longstanding knowledge gaps in potential relationships between nutrients, genetic factors and cardiovascular disease phenotypes. Not only do these studies elucidate the reasons for inconsistencies of prior genetic association studies and support mechanistic relationships between genetic and nutritional factors, but they also provide a framework on which rational preventive nutritional strategies may eventually be based. In spite of this wide-ranging potential, consistent challenges emerge from many of the preceding studies. Addressing these limitations will require replications in larger sample sizes, more extensive genotyping along with deeper, standardized phenotyping, and analyses of interactions in populations of varying ethnicities.

Acknowledgments

Funding

Supported by the National Institutes of Health, National Institute on Aging, Grant Number 5P01AG023394 and NIH/NHLBI grant number HL54776 and NIH/NIDDK DK075030 and contracts 53-K06-5-10 and 58–1950-9-001 from the U.S. Department of Agriculture Research Service. C. Smith is supported by T32 DK007651-19.

References


